AJANTA PHARMA | DIVIS LABORATORIES | AJANTA PHARMA/ DIVIS LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 24.7 | 50.2 | 49.2% | View Chart |
P/BV | x | 6.9 | 13.4 | 51.1% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 112.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-19 |
DIVIS LABORATORIES Mar-19 |
AJANTA PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,422 | 1,639 | 86.7% | |
Low | Rs | 898 | 1,115 | 80.5% | |
Sales per share (Unadj.) | Rs | 233.5 | 186.3 | 125.3% | |
Earnings per share (Unadj.) | Rs | 44.0 | 51.0 | 86.3% | |
Cash flow per share (Unadj.) | Rs | 52.2 | 57.3 | 91.0% | |
Dividends per share (Unadj.) | Rs | 9.00 | 16.00 | 56.3% | |
Dividend yield (eoy) | % | 0.8 | 1.2 | 66.8% | |
Book value per share (Unadj.) | Rs | 255.1 | 261.8 | 97.4% | |
Shares outstanding (eoy) | m | 88.02 | 265.47 | 33.2% | |
Bonus/Rights/Conversions | BB | - | - | ||
Price / Sales ratio | x | 5.0 | 7.4 | 67.2% | |
Avg P/E ratio | x | 26.4 | 27.0 | 97.6% | |
P/CF ratio (eoy) | x | 22.2 | 24.0 | 92.6% | |
Price / Book Value ratio | x | 4.5 | 5.3 | 86.4% | |
Dividend payout | % | 20.5 | 31.4 | 65.2% | |
Avg Mkt Cap | Rs m | 102,081 | 365,592 | 27.9% | |
No. of employees | `000 | 6.8 | 11.8 | 57.4% | |
Total wages/salary | Rs m | 4,307 | 5,423 | 79.4% | |
Avg. sales/employee | Rs Th | 3,022.6 | 4,175.1 | 72.4% | |
Avg. wages/employee | Rs Th | 633.4 | 457.7 | 138.4% | |
Avg. net profit/employee | Rs Th | 569.1 | 1,141.8 | 49.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,554 | 49,463 | 41.6% | |
Other income | Rs m | 211 | 1,556 | 13.5% | |
Total revenues | Rs m | 20,765 | 51,019 | 40.7% | |
Gross profit | Rs m | 5,664 | 18,718 | 30.3% | |
Depreciation | Rs m | 721 | 1,689 | 42.7% | |
Interest | Rs m | 12 | 35 | 33.1% | |
Profit before tax | Rs m | 5,143 | 18,551 | 27.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,273 | 5,023 | 25.3% | |
Profit after tax | Rs m | 3,870 | 13,527 | 28.6% | |
Gross profit margin | % | 27.6 | 37.8 | 72.8% | |
Effective tax rate | % | 24.8 | 27.1 | 91.4% | |
Net profit margin | % | 18.8 | 27.3 | 68.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,812 | 46,501 | 25.4% | |
Current liabilities | Rs m | 3,776 | 8,468 | 44.6% | |
Net working cap to sales | % | 39.1 | 76.9 | 50.8% | |
Current ratio | x | 3.1 | 5.5 | 57.0% | |
Inventory Days | Days | 77 | 131 | 59.2% | |
Debtors Days | Days | 82 | 86 | 95.0% | |
Net fixed assets | Rs m | 14,398 | 25,797 | 55.8% | |
Share capital | Rs m | 175 | 531 | 33.0% | |
"Free" reserves | Rs m | 22,277 | 68,962 | 32.3% | |
Net worth | Rs m | 22,452 | 69,493 | 32.3% | |
Long term debt | Rs m | 7 | 0 | - | |
Total assets | Rs m | 26,962 | 80,383 | 33.5% | |
Interest coverage | x | 444.3 | 531.0 | 83.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.8 | 0.6 | 123.9% | |
Return on assets | % | 14.4 | 16.9 | 85.3% | |
Return on equity | % | 17.2 | 19.5 | 88.5% | |
Return on capital | % | 23.0 | 26.7 | 85.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 24.6 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 12,187 | 0.0% | |
Fx inflow | Rs m | 10,682 | 41,238 | 25.9% | |
Fx outflow | Rs m | 2,102 | 12,405 | 16.9% | |
Net fx | Rs m | 8,580 | 28,833 | 29.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,748 | 9,543 | 39.3% | |
From Investments | Rs m | -2,228 | -6,854 | 32.5% | |
From Financial Activity | Rs m | -1,475 | -2,459 | 60.0% | |
Net Cashflow | Rs m | 45 | 230 | 19.7% |
Indian Promoters | % | 73.8 | 52.0 | 141.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.6 | 11.8 | 13.1% | |
FIIs | % | 7.6 | 19.0 | 40.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.0 | 17.2 | 98.8% | |
Shareholders | 20,968 | 31,796 | 65.9% | ||
Pledged promoter(s) holding | % | 4.4 | 0.0 | - |
Compare AJANTA PHARMA With: WYETH PIRAMAL ENTERPRISES JUBILANT PHARMOVA NEULAND LABS PFIZER
Compare AJANTA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.
For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More